Relay Therapeutics (RLAY) Share-based Compensation (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Share-based Compensation data on file, last reported at $10.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 45.47% year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was -$13.1 million, a 120.53% decrease from a year earlier, with the FY2025 full-year figure at $27.6 million, down 70.68% from the prior year.
• Share-based Compensation for Q1 2026 stood at $10.5 million, up from -$42.4 million in the prior quarter.
• Over the last five years, Share-based Compensation for RLAY reached as high as $27.2 million in Q1 2024 and fell as low as -$42.4 million in Q4 2025.
• Historically, Share-based Compensation has averaged $12.7 million across 5 years, with a median of $15.1 million in 2022.
• Across the five-year window, Share-based Compensation soared 692.67% in 2022 and slumped 340.68% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $9.5 million in 2022, then soared by 102.55% to $19.3 million in 2023, then decreased by 8.47% to $17.6 million in 2024, then sank by 340.68% to -$42.4 million in 2025, then jumped by 124.83% to $10.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $10.5 million in Q1 2026, -$42.4 million in Q4 2025, and $9.5 million in Q3 2025.